Recently, the "Vaccine Management Law" was passed at the 11th meeting of the 13th NPC Standing Committee. This is the first special legislation in China in the field of vaccine management, and the regulation will take effect on December 1, 2019.
The new law of the vaccine industry has arrived, how will listed companies respond? On June 28, Du Weimin, chairman and president of Kangtai Bio, said at the groundbreaking ceremony of Kangtai Bio ’s new headquarters base, Kangtai Bio supported the country to strengthen vaccine production, circulation, and vaccination The management of the whole process has made sufficient preparations to welcome the formal implementation of the Vaccine Management Law and jointly build a firewall for the lives and health of the people.
Before the approval of the Vaccine Management Law, on April 18, 2019, Kangtai Biology, as one of the sponsors, jointly held the "Guangdong Province Vaccine Industry Self-Regulation Mechanism Establishment Meeting" with two other vaccine manufacturers in Guangdong Province. The "Guangdong Provincial Vaccine Industry Self-Regulatory Organization" was established and the "Vaccine Self-Regulatory Agreement" was jointly signed, advocating the establishment of a new pattern of "co-construction, co-governance and sharing" of social governance in the vaccine industry. The signing place of the self-regulatory agreement was at the headquarter of Kangtai Biology, relevant leaders of Guangdong Drug Administration and Shenzhen Market Supervision Administration witnessed together.
In terms of improving hardware conditions, Kangtai Biology has also made repeated moves. At the recent groundbreaking ceremony of Kangtai Bio ’s new headquarters base, Du Weimin revealed that the base will be built as a complex integrating R & D, incubation, office and display, with a total investment of 2 billion yuan and an area of 17,300 square meters, including A 37-story R & D building.
In October 2018, Kangtai Biological Global Vaccine R & D and Production Base, which cost 850 million and covers an area of more than 60,000 square meters, was officially opened. The base is the largest vaccine production monomer building in Asia, providing a good environment for vaccine research and development, safe production, inspection, and storage.